Alkem Lab
Alkem Lab Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #62 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 4 strong
The short version
International Business: Sustainable double-digit growth expected, driven by smaller markets like Germany (35-40% growth), Chile, and Australia. India business growth is expected around 12% for the full year, slightly better than previous guidance.
From Alkem Lab's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- International Business: Sustainable double-digit growth expected, driven by smaller markets like Germany (35-40% growth), Chile, and Australia. U.S. business remains flat to high single-digit growth due to pricing pressure and currency effects.
- U.S. Market: Anticipated growth in high single to mid-single digits in FY27, helped by currency benefits. No major volume expansion seen in last 12-24 months.
- India Business: Branded formulations expected to grow around 12%; Trade Generics growth slower—late single digits anticipated with disciplined execution.
2 more points from Alkem Lab's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Alkem Lab said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company currently has reasonable capacity at its CDMO facility in the U.S., with some specialized technology; however, it is relatively small.
- Future capex will be required at the CDMO facility to ramp up production and achieve economies of scale, but this is not expected to happen in the current fiscal year.
- No plans for acquisitions in the orthopedics or MedTech segment at present; focus is on ramping up existing operations.
- Overall, capex related to CDMO expansion is planned but timed based on business growth and scale requirements.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alkem Lab said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The management mentioned they would provide this information later.
- For the U.S. CDMO (Contract Development and Manufacturing Organization) business, the revenue breakeven is expected at an annualized USD 25-30 million run rate.
- The CDMO business has a decent project pipeline but the sales cycle is long and lumpy, dependent on client funding and clinical trial progress.
- The company anticipates CDMO revenues to start rising in FY27 and FY28, with the USD 30 million revenue target expected by FY28.
2 more points from Alkem Lab's call on order book
Create a free account to keep reading this call
Alkem Lab — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹3.6K Cr, net profit ₹251 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alkem Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alkem Lab and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alkem Lab Q1 FY27 results?
International Business: Sustainable double-digit growth expected, driven by smaller markets like Germany (35-40% growth), Chile, and Australia. India business growth is expected around 12% for the full year, slightly better than previous guidance.
What is Alkem Lab share price analysis?
Alkem Lab currently shows a below-average growth signal. The stock trades at a P/E of 28.8 with a market cap of ₹65,360 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alkem Lab planning capital expenditure?
The company currently has reasonable capacity at its CDMO facility in the U.S., with some specialized technology; however, it is relatively small.
Keep Alkem Lab on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.